Comparison of On-Treatment Platelet Reactivity Between Triple Antiplatelet Therapy With Cilostazol and Standard Dual Antiplatelet Therapy in Patients Undergoing Coronary Interventions: A Meta-Analysis
Conclusion:
Addition of cilostazol to conventional dual antiplatelet therapy significantly lowers platelet reactivity and may explain a decrease in thromboembolic events following coronary intervention; however, additional studies evaluating clinical outcomes will be helpful to determine the benefit of triple antiplatelet therapy.
Source: Journal of Cardiovascular Pharmacology and Therapeutics - Category: Cardiology Authors: Panchal, H. B., Shah, T., Patel, P., Albalbissi, K., Molnar, J., Coffey, B., Khosla, S., Ramu, V. Tags: Clinical Studies Source Type: research
More News: Angioplasty | Aspirin | Cardiology | Cardiovascular | Cilostazol | Clopidogrel | Coronary Angioplasty | Drugs & Pharmacology | Heart | Percutaneous Coronary Intervention | Plavix | Study